Nexvet,Fujifilm Diosynth Sign Biologics Mfg Pact
Nexvet Biopharma, a veterinary biologics developer, has signed a manufacturing agreement with Fujifilm Diosynth Biotechnologies to provide future clinical-scale biomanufacturing services for Nexvet’s advanced product candidates, NV-01 and NV-02, being developed for chronic pain management indications in dogs and cats. The contract also allows for Fujifilm to become the commercial manufacturer of these product candidates.
In addition to the recent appointment of Dr. JÃ¼rgen Horn as chief product development officer, Nexvet has appointed Ray O’Connor as vice president of technical operations to oversee manufacturing scale-up. Mr. O’Connor is based in Dublin, Ireland. Nexvet is also recruiting other key manufacturing roles in product quality and process development, all expected to be based in Ireland.
Mr O’Connor’s previous roles include serving as head of manufacturing for Jazz Pharmaceuticals, as a general manager at the animal health company, Norbrook Laboratories, and in a series of roles in both Europe and the United States with Pfizer (Wyeth Biopharma), Baxter Biopharma, and Schering-Plough.
Source: Nexvet Biopharma